<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574427</url>
  </required_header>
  <id_info>
    <org_study_id>N19IFC</org_study_id>
    <nct_id>NCT04574427</nct_id>
  </id_info>
  <brief_title>INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue</brief_title>
  <acronym>INFLUENCE</acronym>
  <official_title>INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we evaluate the feasibility of intraoperative visualization of penile and&#xD;
      tongue tumours using the fluorescent tracer EMI-137.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, non-randomized, prospective interventional pilot study. Feasibility&#xD;
      of intraoperatively visualizing tumour (margins) in penile and tongue tumours using EMI-137&#xD;
      will be investigated. Patients, ≥ 18 years of age, with ≥T1 penile or tongue cancer&#xD;
      undergoing primary tumour surgery will be included. All patients will receive an intravenous&#xD;
      bolus injection of EMI-137 prior to surgery. Main study parameters/endpoints are:&#xD;
      Intraoperative visualization of primary penile or tongue tumours using a dedicated clinical&#xD;
      fluorescence camera. The in vivo detected fluorescence signal will be correlated to ex vivo&#xD;
      measurements and pathological assessment of the ex-cised tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Tracer not available.&#xD;
  </why_stopped>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">November 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tumour visualization by means of c-MET targeted fluores-cence imaging</measure>
    <time_frame>peri-operative</time_frame>
    <description>The feasibility of intraoperative tumour visualization by means of c-MET targeted fluores-cence imaging will be evaluated, and the imaging result will be correlated to the level of c-MET expression determined using standard immunohistochemistry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymph node visualization by means of c-MET targeted fluores-cence imaging</measure>
    <time_frame>peri-operative</time_frame>
    <description>Detection and visualization of lymph node metastases in penile and tongue tumour patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysplasia or Cis by means of c-MET targeted fluores-cence imaging</measure>
    <time_frame>Peri-operative</time_frame>
    <description>Identification of dysplasia or carcinoma in situ in penile and tongue tumours.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Penile Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with tongue cancer scheduled for primary tumour resection OR Patients with penile&#xD;
        cancer scheduled for primary tumour resection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent, prior to performing any protocol related procedures.&#xD;
&#xD;
          -  Age ≥ 18 years at time of study entry.&#xD;
&#xD;
          -  ≥ T1 penile or tongue squamous cell cancer&#xD;
&#xD;
          -  Scheduled for surgical primary tumour resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study.&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Abstaining from usage of two forms of barrier contraceptive or actively planning&#xD;
             pregnancy within 90 days.&#xD;
&#xD;
          -  Severe kidney insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baris Karakullukcu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute / Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgery</keyword>
  <keyword>fluorescent c-met tracer</keyword>
  <keyword>penile</keyword>
  <keyword>tongue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

